GOTHENBURG, Sweden, Oct. 18, 2024 /PRNewswire/ -- "The order intake increased by 10.0%, of which organic growth was 7.4%. All regions reported a positive performance," says Mattias Perjos, President & CEO at Getinge. The medtech company's net sales increased by 3.5%, of which the organic increase was 0.2%, while the operating margin weakened compared with last year.

The global market for Getinge's products is still strong and during the quarter order intake increased by 10.0%, of which organic growth was 7.4%. All regions reported a positive performance, with particularly strong growth in consumables in Cardiopulmonary and ventilators in Critical Care and Infection Control. This was also the case for Bio-Processing, with double-digit growth in the organic order intake both in the US and in China.

GOTHENBURG, Sweden, Oct. 18, 2024 /PRNewswire/ -- "The order intake increased by 10.0%, of which organic growth was 7.4%. All regions reported a positive performance," says Mattias Perjos, President & CEO at Getinge. The medtech company's net sales increased by 3.5%, of which the organic increase was 0.2%, while the operating margin weakened compared with last year.

The global market for Getinge's products is still strong and during the quarter order intake increased by 10.0%, of which organic growth was 7.4%. All regions reported a positive performance, with particularly strong growth in consumables in Cardiopulmonary and ventilators in Critical Care and Infection Control. This was also the case for Bio-Processing, with double-digit growth in the organic order intake both in the US and in China.

Getinge has today completed the previously announced acquisition of 100% of the shares of Paragonix Technologies, Inc.

GOTHENBURG, Sweden, Sept. 11, 2024 /PRNewswire/ -- On August 22, 2024, Getinge announced that it had entered into an agreement to acquire Paragonix Technologies, Inc., a leading U.S. company in organ transport products and services, for a total purchase price estimated at USD 477 million, including upfront and currently estimated earn-outs.

All conditions for the transaction have now been fulfilled, whereupon the transaction was completed today.

Today, Getinge announces an agreement to acquire 100% of Paragonix Technologies, Inc., a leading organ transport products and services company in the United States for an aggregated purchase price, including upfront and earn out payments, estimated to approximately USD 477 million.

GOTHENBURG, Sweden, Aug. 23, 2024 /PRNewswire/ -- With the acquisition of Paragonix Technologies – a pioneer and innovator in organ transport and preservation – Getinge marks its entry into a rapidly advancing field driven by rising transplant volumes, technological innovations and evolving clinical practices. The acquisition aligns with Getinge's broader strategy to expand its portfolio into high growth markets that complement and enhance its acute heart and lung support offering already being used in connection with transplantation, positioning the company at the forefront of the fast-growing organ preservation and transportation market.

Today, Getinge announces an agreement to acquire 100% of Paragonix Technologies, Inc., a leading organ transport products and services company in the United States for an aggregated purchase price, including upfront and earn out payments, estimated to approximately USD 477 million.

GOTHENBURG, Sweden, Aug. 22, 2024 /PRNewswire/ -- With the acquisition of Paragonix Technologies – a pioneer and innovator in organ transport and preservation – Getinge marks its entry into a rapidly advancing field driven by rising transplant volumes, technological innovations and evolving clinical practices. The acquisition aligns with Getinge's broader strategy to expand its portfolio into high growth markets that complement and enhance its acute heart and lung support offering already being used in connection with transplantation, positioning the company at the forefront of the fast-growing organ preservation and transportation market.